AstraZeneca - Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers - Marketscreener.com
| ZEG Stock | 126.45 2.00 1.56% |
Slightly above 61% of AstraZeneca PLC's investor base is looking to short. The analysis of current outlook of investing in AstraZeneca PLC suggests that many traders are alarmed regarding AstraZeneca PLC's prospects. AstraZeneca PLC's investing sentiment can be driven by a variety of factors including economic data, AstraZeneca PLC's earnings reports, geopolitical events, and overall market trends.
AstraZeneca |
AstraZeneca - Imfinzi plus Imjudo approved in the EU for patients with advanced liver and non-small cell lung cancers Marketscreener.com
Read at news.google.com
 |
AstraZeneca PLC Fundamental Analysis
We analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Z Score
Z Score Comparative Analysis
AstraZeneca PLC is currently under evaluation in z score category among its peers. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
AstraZeneca PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AstraZeneca PLC stock to make a market-neutral strategy. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics with similar companies.
Peers
AstraZeneca PLC Related Equities
| M0G | FIREWEED METALS | 1.06 | ||||
| DFA1 | DAIRY FARM | 0.91 | ||||
| 4D7 | Daito Trust | 1.80 | ||||
| UAO | Sterling Construction | 1.88 | ||||
| 3TY | TITAN MACHINERY | 2.04 | ||||
| 3TY | Titan Machinery | 2.04 | ||||
| AOC | Aluminumof China | 3.51 |
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.